COMMUNIQUÉS West-GlobeNewswire

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
08/05/2025
New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to [...]
Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons
08/05/2025
Three-year program examined opportunities to integrate artificial intelligence technology into future generations of ReWalk Exoskeletons MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- [...]
Exagen Inc. Prices Public Offering of Common Stock
08/05/2025
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3 [...]
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration
08/05/2025
Meeting to Take Place on July 25, 2025 Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL [...]
Arialief Complaints Exposed: 2025 User Reviews Analyzed and Verified
08/05/2025
Arialief for Neuropathy is a doctor-recommended joint support supplement made with natural, clinically backed ingredients like turmeric, glucosamine, and Boswellia. Designed to reduce inflammation, relieve joint pain, [...]
STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference
08/05/2025
HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025
08/05/2025
Trial achieves unprecedented and clinically meaningful socialization gains in adolescents and young adults, addressing core autism symptoms currently lacking FDA-approved therapies NEW YORK, May 08, 2025 (GLOBE NEWSWIRE [...]
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG- [...]
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
08/05/2025
Approximately 15 million USD Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases Oryzon will explore Aggression in specific subsets of Autism Spectrum Disorder [...]
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
08/05/2025
IND clearance and initiation of global basket trial exploring AlloNK ® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore [...]
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
08/05/2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer [...]
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
08/05/2025
– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and [...]
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
08/05/2025
Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one [...]
Stryker declares an $0.84 per share quarterly dividend
08/05/2025
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the [...]
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
08/05/2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that its [...]
Merus to Present at BofA Securities 2025 Health Care Conference
08/05/2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics [...]
RAPT Therapeutics Reports First Quarter 2025 Financial Results
08/05/2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, [...]
Cassava Reports Q1 2025 Financials Results, Provides Business Update
08/05/2025
License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 [...]
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
08/05/2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]

Pages